Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.

OBJECTIVE To assess whether hydroxychloroquine can delay renal damage development in lupus nephritis patients. METHODS Lupus nephritis patients (n = 256) from the LUpus in MInorities, NAture versus nurture study (n = 635), a multiethnic cohort of African Americans, Hispanics, and Caucasians, age > or =16 years with disease duration < or =5 years at baseline (T0) were studied. Renal damage was defined using the Systemic Lupus International Collaborating Clinics Damage Index (> or =1 of the following lasting at least 6 months: estimated/measured glomerular filtration rate <50%, 24-hour proteinuria > or =3.5 gm and/or end-stage renal disease, regardless of dialysis or transplantation). Patients with renal damage before T0 were excluded (n = 53). The association between hydroxychloroquine use and renal damage (as defined, or omitting proteinuria) was estimated using Cox proportional regression analyses adjusting for potential confounders. Kaplan-Meier survival curves based on hydroxychloroquine intake or the World Health Organization (WHO) class glomerulonephritis were also derived. RESULTS Sixty-three (31.0%) of the 203 patients included developed renal damage over a mean +/- SD disease duration of 5.2 +/- 3.5 years. The most frequent renal damage domain item was proteinuria. Patients who received hydroxychloroquine (79.3%) exhibited a lower frequency of WHO class IV glomerulonephritis, had lower disease activity, and received lower glucocorticoid doses than those who did not take hydroxychloroquine. After adjusting for confounders, hydroxychloroquine was protective of renal damage occurrence in full (hazard ratio [HR] 0.12, 95% confidence interval [95% CI] 0.02-0.97, P = 0.0464) and reduced (HR 0.29, 95% CI 0.13-0.68, P = 0.0043) models. Omitting proteinuria provided comparable results. The cumulative probability of renal damage occurrence was higher in those who did not take hydroxychloroquine and those classified as WHO class IV glomerulonephritis (P < 0.0001). CONCLUSION After adjusting for possible confounding factors, the protective effect of hydroxychloroquine in retarding renal damage occurrence in systemic lupus erythematosus is still evident.

[1]  D. Isenberg,et al.  An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. , 2006, Rheumatology.

[2]  Martin Schumacher,et al.  Evidence from nonrandomized studies: a case study on the estimation of causal effects. , 2008, American journal of epidemiology.

[3]  D. Symmons,et al.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[4]  S Suissa,et al.  Predictors of one year outcome in lupus nephritis: the importance of renal biopsy. , 1991, The Quarterly journal of medicine.

[5]  M. Petri.  Biochemical characterization of ADP-ribose polymer metabolism in SLE. , 1996 .

[6]  M. Manivasagar,et al.  Systemic lupus erythematosus in Malaysia: a study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups , 1997, Lupus.

[7]  J. Reveille,et al.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. , 2006, Rheumatology.

[8]  M. Petri.  Hopkins Lupus Cohort. 1999 update. , 2000, Rheumatic diseases clinics of North America.

[9]  Kelly D. Smith.  Lupus nephritis: toll the trigger! , 2006, Journal of the American Society of Nephrology : JASN.

[10]  D. Gladman,et al.  The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[11]  J. Reveille,et al.  Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis , 2002, Lupus.

[12]  M. Petri,et al.  Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. , 1991 .

[13]  K. Siddle,et al.  Chloroquine Extends the Lifetime of the Activated Insulin Receptor Complex in Endosomes* , 1997, The Journal of Biological Chemistry.

[14]  D. Wallace,et al.  Antimalarials—the ‘real‘ advance in lupus , 2001, Lupus.

[15]  D. Wallace,et al.  Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? , 1987, Arthritis and rheumatism.

[16]  I. Pilowsky,et al.  Dimensions of illness behaviour as measured by the Illness Behaviour Questionnaire: a replication study. , 1993, Journal of psychosomatic research.

[17]  D. Boumpas,et al.  Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. , 1994, Kidney international.

[18]  M. Petri.  Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. , 1996, Scandinavian journal of rheumatology.

[19]  C. Bombardier,et al.  Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. , 1994, The Journal of rheumatology.

[20]  J. Reveille,et al.  Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort. , 2008, Rheumatology.

[21]  M. Ramos-Casals,et al.  Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival , 2008, Lupus.

[22]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[23]  A. Camargo-Coronel,et al.  Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus , 2007, Lupus.

[24]  J. Reveille,et al.  A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. , 2007, Arthritis and rheumatism.

[25]  J. Reveille,et al.  Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. , 2005, Arthritis and rheumatism.

[26]  L. Sargeant,et al.  The Outcome of Lupus Nephritis in Jamaican Patients , 2007, The American journal of the medical sciences.

[27]  J. Kremer,et al.  Chloroquine inhibits proinflammatory cytokine release into human whole blood. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[28]  R. Haynes,et al.  The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial. , 2002, Diabetes research and clinical practice.

[29]  G. Ruiz-Irastorza,et al.  Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus , 2006, Lupus.

[30]  L. Aarden,et al.  IMMUNOLOGY OF DNA. III. CRITHIDIA LUCILIAE, A SIMPLE SUBSTRATE FOR THE DETERMINATION OF ANTI‐dsDNA WITH THE IMMUNOFLUORESCENCE TECHNIQUE * , 1975, Annals of the New York Academy of Sciences.

[31]  E. Harris,et al.  Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. , 1990, American journal of clinical pathology.

[32]  D. Heinegård,et al.  Determination of serum creatinine by a direct colorimetric method. , 1973, Clinica chimica acta; international journal of clinical chemistry.

[33]  S. Studenski,et al.  Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. , 1992, Archives of internal medicine.

[34]  G. Hughes,et al.  Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients , 2003, Medicine.

[35]  M. Liang,et al.  Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus. , 2000, The Journal of rheumatology.

[36]  Til Stürmer,et al.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. , 2006, Journal of clinical epidemiology.

[37]  J. Reveille,et al.  Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. , 2003, Rheumatology.

[38]  J. Reveille,et al.  Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) , 2007, Annals of the rheumatic diseases.

[39]  B. Beutler,et al.  TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity , 2007, Nature Medicine.

[40]  J. Reveille,et al.  Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. , 2008, Rheumatology.

[41]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[42]  E. Soriano,et al.  The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With Systemic Lupus Erythematosus: Ethnic and Disease Heterogeneity Among “Hispanics” , 2004, Medicine.

[43]  E. Tsakonas,et al.  A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus , 1998 .

[44]  C. Gordon,et al.  SLE patients with renal damage incur higher health care costs. , 2007, Rheumatology.

[45]  M. Liang,et al.  Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. , 1989, Arthritis and rheumatism.

[46]  J. Reveille,et al.  Systemic lupus erythematosus in three ethnic groups: III A comparison of characteristics early in the natural history of the LUMINA cohort , 1999 .

[47]  L. Magder,et al.  Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis , 2006, Lupus.

[48]  C. Lau,et al.  Damage accrual in southern Chinese patients with systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[49]  D. Gladman,et al.  Mortality in systemic lupus erythematosus. , 2006, The Journal of rheumatology. Supplement.

[50]  R. Lafyatis,et al.  Antimalarial agents: closing the gate on Toll-like receptors? , 2006, Arthritis and rheumatism.

[51]  J. Vasiliades,et al.  Reaction of alkaline sodium picrate with creatinine: I. Kinetics and mechanism of formation of the mono-creatinine picric acid complex. , 1976, Clinical chemistry.